Brief: Metacrine Initiates Phase 2a Combination Trial Of MET409 With Empagliflozin In Patients With Type 2 Diabetes And NASH
05/01/2021 12:26
Jan 5 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE INITIATES PHASE 2A COMBINATION TRIAL OF MET409
WITH
EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND NASH
* METACRINE, INC. - METACRINE EXPECTS TO REPORT TOPLINE DATA
IN
FIRST HALF OF 2022
Source text for Eikon: ID:nGNX7wn0df
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions